These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25145672)

  • 1. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
    Wang S; Sun W; Zhao Y; McEachern D; Meaux I; Barrière C; Stuckey JA; Meagher JL; Bai L; Liu L; Hoffman-Luca CG; Lu J; Shangary S; Yu S; Bernard D; Aguilar A; Dos-Santos O; Besret L; Guerif S; Pannier P; Gorge-Bernat D; Debussche L
    Cancer Res; 2014 Oct; 74(20):5855-65. PubMed ID: 25145672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
    Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
    Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
    Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
    Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
    Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
    Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
    Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
    Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy.
    Cheng J; Yan Z; Jiang K; Liu C; Xu D; Lyu X; Hu X; Zhang S; Zhou Y; Li J; Zhao Y
    J Med Chem; 2023 Dec; 66(24):16991-17025. PubMed ID: 38062557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Synthesis of Complex Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2-p53 Inhibitors.
    Gollner A; Weinstabl H; Fuchs JE; Rudolph D; Garavel G; Hofbauer KS; Karolyi-Oezguer J; Gmaschitz G; Hela W; Kerres N; Grondal E; Werni P; Ramharter J; Broeker J; McConnell DB
    ChemMedChem; 2019 Jan; 14(1):88-93. PubMed ID: 30458062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma.
    Yi H; Yan X; Luo Q; Yuan L; Li B; Pan W; Zhang L; Chen H; Wang J; Zhang Y; Zhai Y; Qiu MZ; Yang DJ
    J Exp Clin Cancer Res; 2018 May; 37(1):97. PubMed ID: 29716622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 4-imidazolidinone-containing compounds as potent inhibitors of the MDM2/p53 interaction.
    Lin Z; Liu C; Yan Z; Cheng J; Wang X; Zhou F; Lyu X; Zhang S; Zhang D; Meng X; Zhao Y
    Eur J Med Chem; 2024 Apr; 270():116366. PubMed ID: 38581730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis.
    Fedorova O; Daks A; Petrova V; Petukhov A; Lezina L; Shuvalov O; Davidovich P; Kriger D; Lomert E; Tentler D; Kartsev V; Uyanik B; Tribulovich V; Demidov O; Melino G; Barlev NA
    Cell Cycle; 2018; 17(15):1917-1930. PubMed ID: 30109812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum
    Liu W; Ma Y; He Y; Liu Y; Guo Z; He J; Han X; Hu Y; Li M; Jiang R; Wang S
    J Med Chem; 2024 Jun; 67(11):9645-9661. PubMed ID: 38776419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
    Ho JNHG; Schmidt D; Lowinus T; Ryoo J; Dopfer EP; Gonzalo Núñez N; Costa-Pereira S; Toffalori C; Punta M; Fetsch V; Wertheimer T; Rittmann MC; Braun LM; Follo M; Briere C; Vinnakota JM; Langenbach M; Koppers F; Shoumariyeh K; Engel H; Rückert T; Märklin M; Holzmayer S; Illert AL; Magon F; Andrieux G; Duquesne S; Pfeifer D; Staniek J; Rizzi M; Miething C; Köhler N; Duyster J; Menssen HD; Boerries M; Buescher JM; Cabezas-Wallscheid N; Blazar BR; Apostolova P; Vago L; Pearce EL; Becher B; Zeiser R
    Blood; 2022 Sep; 140(10):1167-1181. PubMed ID: 35853161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis).
    Wang Z; Zhang X; Luo Y; Song Y; Xiang C; He Y; Wang K; Yu Y; Wang Z; Peng W; Ding Y; Liu S; Wu C
    Cell Death Dis; 2024 May; 15(5):375. PubMed ID: 38811536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction.
    Shiheido H; Takashima H; Doi N; Yanagawa H
    PLoS One; 2011 Mar; 6(3):e17898. PubMed ID: 21423613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2-P53 Interaction Inhibitor with Cisplatin Enhances Apoptosis in Colon and Prostate Cancer Cells In-Vitro.
    Gupta A; Behl T; Heer HR; Deshmukh R; Sharma PL
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3341-3351. PubMed ID: 31759358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.
    Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2016 Oct; 63(10):1744-52. PubMed ID: 27238606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving anticancer activity towards colon cancer cells with a new p53-activating agent.
    Raimundo L; Espadinha M; Soares J; Loureiro JB; Alves MG; Santos MMM; Saraiva L
    Br J Pharmacol; 2018 Oct; 175(20):3947-3962. PubMed ID: 30076608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule NMD and MDM2 inhibitors synergistically trigger apoptosis in HeLa cells.
    Li Y; Wan L; Li H; Tang X; Xu S; Sun G; Huang W; Tang M
    Mol Cells; 2024 Jul; 47(7):100079. PubMed ID: 38871298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designed novel nuclear localizing anticancer peptide targets p53 negative regulator MDM2 protein.
    Mukherjee N; Bhunia D; Garai PK; Mondal P; Barman S; Ghosh S
    J Pept Sci; 2024 Jan; 30(1):e3535. PubMed ID: 37580909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.
    Wang W; Qin JJ; Voruganti S; Srivenugopal KS; Nag S; Patil S; Sharma H; Wang MH; Wang H; Buolamwini JK; Zhang R
    Nat Commun; 2014 Oct; 5():5086. PubMed ID: 25271708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.